Alzheimer's disease (AD) is a neurodegenerative disorder and the most common type of age-related dementia. Cognitive decline, beta-amyloid (Aβ) accumulation, neurofibrillary tangles, and neuroinflammation are the main pathophysiological characteristics of AD. Minocycline is a tetracycline derivative with anti-inflammatory properties that has a neuroprotective effect. The aim of this study was to evaluate the effect of minocycline on memory, neurotrophins and neuroinflammation in an animal model of AD induced by the administration of Aβ (1-42) oligomer. Male BALB/c mice were treated with minocycline (50 mg/kg) via the oral route for a total of 17 days, 24 h after intracerebroventricular administration of Aβ (1-42) oligomer. At the end of this period, was performed the radial maze test, and 24 h after the last minocycline administration, serum was collected and the cortex and hippocampus were dissected for biochemical analysis. The administration of minocycline reversed the memory impairment caused by Aβ (1-42). In the hippocampus, minocycline reversed the increases in the levels of interleukin (IL-1β), Tumor Necrosis Factor-alpha (TNF-α) and, IL-10 caused by Aβ (1-42). In the cortex, AD-like model increase the levels of IL-1β, TNF-α and, IL-4. Minocycline treatment reversed this. In the serum, Aβ (1-42) increased the levels of IL-1β and IL-4, and minocycline was able to reverse this action, but not to reverse the decrease of IL-10 levels. Minocycline also reversed the increase in the levels of Brain-derived neurotrophic factor (BDNF) in the hippocampus caused by Aβ (1-42), and reduced Nerve Growth Factor (NGF) increases in the total cortex. Therefore, our results indicate that minocycline causes improvements in the spatial memory, and cytokine levels were correlated with this effect in the brain it. Besides this, minocycline reduced BDNF and NGF levels, highlighting the promising effects of minocycline in treating AD-like dementia.
Introduction
Alzheimer's disease (AD) is a neurodegenerative disorder in which the main risk factor is age, with data showing a considerable increase in incidence rates after the age of 60 years. The chance of developing the disease increases as people get older (Dubois et al., 2016; Herrup, 2010; Savva et al., 2009) . AD is the most common type of age-related dementia and is accompanied by memory loss and cognitive impairment (Ismail et al., 2011) . AD causes visuospatial disorientation associated with cortical atrophy, which in turn leads to visuospatial memory impairments (Foxe et al., 2016; Mapstone et al., 2003) . The Hippocampus and caudate nucleus are critical regions involved in spatial memory and navigation strategies (Craig and McBain, 2015; Dahmani and Bohbot, 2015) . Atrophy of the hippocampus is a welldescribed feature of AD, and is directly associated with an increased risk towards the development and progression of AD (Apostolova et al., 2006; Chetelat et al., 2008; Mungas et al., 2005; Teipel et al., 2013) .
AD initializes with a decline in episodic memory that is often mistaken for normal cognitive deficiencies due to aging, and is subsequently classified in the following stages: mild cognitive impair-ment (MCI), early AD (EAD), and late-stage AD (LAD) (Butterfield et al., 2013) . The disease is neurodegenerative and progressive, with different rates of progression being observed amongst AD patients (Zhao et al., 2014) . However, in the last stage of the disease, the ultimate outcome is death. Presently, the only drug treatments approved for use with AD are forms of palliative care, acting to prevent any worsening of the patients' symptoms. There is currently no treatment leading to a cure of the disease (Ramirez-Bermudez, 2012) .
The most described pathophysiological features of AD are the extracellular accumulation of beta-amyloid peptide (Aβ1-42) and neurofibrillary tangles (NFT) (Sery et al., 2013) . The accumulation of Aβ1-42 peptide forms extracellular plaques called "senile plaques" that occur due to an increased and abnormal processing of the Aβ precursor protein (APP), which leads to an interruption of synapse function (Buoso et al., 2010) . When α-secretase cleaved APP, it forms a nontoxic soluble extracellular fragment, sAPPα. When β-secretase cleaved APP, it generates a soluble extracellular fragment called sAPPβ. The latter γ-secretase forming Aβ 40-42 fragments, called Aβ or Aβ oligomers (Aβ aggregated form). It is toxic within the CNS, and can lead to neuroinflammation via the activation of the innate immune system (Heneka et al., 2014; Puzzo et al., 2015) .
Neuroinflammation is an important pathophysiological feature of AD. It has recently attracted a number of studies, since it has been discovered that there are many polymorphisms within the genes related to the inflammatory responses, endocytosis and phagocytosis that have been observed in AD patients (Lambert et al., 2013) . Neuroinflammation is involved in several neurodegenerative processes due to the production of inflammatory factors such as cytokines and chemokines (Tan et al., 2013) . In addition, many changes occur in the levels of neurotrophins (Budni et al., 2015a) . Increases in the levels of proinflammatory cytokines have been observed in the serum, brain and cerebrospinal fluid (CSF) of AD patients (Dursun et al., 2015; Jack et al., 2013; Zhang et al., 2013) . Many studies have directly associated the levels of cytokines with the cognitive decline seen in AD patients at all stages, as it happens in older people without cognitive impairment or those suffering with mild cognitive impairment (Harries et al., 2012; Solfrizzi et al., 2006; Westin et al., 2012) . However, there are no drugs approved for neuroinflammation in AD.
Minocycline is a tetracycline that possesses anti-inflammatory properties that are independent of its antimicrobial action. This drug is able to cross the blood brain barrier and presents a neuroprotective capacity (Kuang et al., 2009) . In preclinical studies, minocycline has been shown to provide neuroprotective activity in various neurodegenerative diseases such as in Parkinson's disease (Wu et al., 2002) , amyotrophic lateral sclerosis (Zhu et al., 2002 ), Huntington's disease (Chen et al., 2000) and AD, particularly within the transgenic mice used in some studies (Choi et al., 2007; Noble et al., 2009; Parachikova et al., 2010) . Thus, some of the mechanisms of action for minocycline are already being studied (Budni et al., 2016) . In addition, there is currently a phase II clinical trial taking place that is testing the effects of minocycline on AD patients (London, 2015) . Therefore, the aim of this study was to evaluate the effects that minocycline has on memory and the levels of cytokines and neurotrophins in an AD-like animal model of dementia induced via the administration of amyloid β (1-42) oligomers.
Material and methods

Animals
Male BALB/c mice (100 day old, weighing 30-40 g) were used in this study. The animals were kept under standard conditions of a 12-h light/dark cycle, with food and water available ad libitum. They were housed in plastic cages with soft bedding. All manipulations were performed between 8:00 a.m. and 4:00 p.m. Local ethics committee (Ethics Committee on Animal Use -CEUA of the Universidade do Extremo Sul Catarinense) approved this study. ll experimental procedures were performed according to the NIH Guide for the Care and Use of Laboratory Animals, as well as under the Brazilian Society for Neuroscience and Behavior recommendations for animal care.
Administration of Amyloid β (1-42) oligomer
The β-amyloid 1-42 peptide (Tocris Bioscience, Bristol, UK) was dissolved in a PBS solution (137 mM NaCl; 10 mM Na 2 HPO 4; 1.8 mM KH 2 PO 4; 2.7 mM KCl; pH 7.5) at a concentration of 1 μg/μL. It was then incubated for 7 days at 37°C to allow the formation of birefringent fibril-like structures (oligomers Aβ) (Resende et al., 2008; Ruiz-Muñoz et al., 2011; Ueda et al., 1994) . The solution was stored at −20°C until use, whereby it was diluted to the final dose of 400 pmol/site in artificial cerebrospinal fluid (ACSF) (24 mM NaCl; 2.5 mM KCl; 2.0 mM MgSO4; 1.25 mM KH2PO4; 26 mM NaHCO3; 10 mM glucose; 4 mM sucrose) before being used. The mice were anesthetized with isoflurane, and the Aβ oligomers were injected via microinjections using a Hamilton 10 μl syringe connected to a specially made 28-gauge stainless steel needle that was 3 mm in length. The needle was inserted unilaterally at a position 1 mm lateral to bregma, 1 mm posterior and 2.5 mm deep from the pial surface. The needle was inserted directly through the skin and skull and into the lateral ventricle, which was targeted by visualizing an equilateral triangle between the eyes and the center of the skull to locate the bregma (Gomes et al., 2013; Laursen and Belknap, 1986) . The Aβ oligomers were injected in a volume of 4 μl over a period of 10s, followed by a 10 s delay to allow diffusion.
Drugs and treatment
Minocycline (Minocycline hydrochloride; Ranbaxy Laboratories, Madhya Pradesh, Índia) was diluted in water for administration at a dose of 50 mg/kg of body weight, using the oral route. It was administered by gavage, once a day, for a period of 17 days (Ferretti et al., 2012; Garwood et al., 2010) . The treatment started 24 h after the injection of Aβ 1-42 oligomer. The animals were randomized into four groups: Control animals (receiving ACSF i. . Testing using the radial arm-maze task started on the 14th day after Aβ 1-42 administration and ended on the 18th day, as explained below. On the day following the radial arm-maze task, which was twenty-four hours after the last administration of minocycline, serum was collected and the animals were then killed by decapitation. The dissected animals' cortex and hippocampus were frozen in liquid nitrogen and stored at − 80°for biochemical analysis.
Radial arm-maze task
On the 14th day after the administration of Aβ (1-42) oligomer, the animals were subjected to the radial arm-maze task. The radial armmaze apparatus has 8-arms, which are numbered from 1 to 8 (48 × 12 cm), extending radially from a central area (32 cm diameter). The apparatus is placed 50 cm above the floor, and geometric shapes were positioned in the straight arms where the food was placed (visual cues). On the first day, each animal was placed in the apparatus for a total of 5 min, allowed only to explore, after returned to its cage. Prior to performing the maze task, the animals were kept on a restricted diet, and their body weight was maintained at 85% of their free-feeding weight over a period of one week, with only water being available ad libitum. On the first day of actual testing, the animals were placed in the apparatus, where food (cereal) had already been deposited in four of the eight arms, the food bearing arms having visual cues at the end of each arm. Over a period of 10 min, the entry into each arm (total errors to find food) and the time each animal took to find the 4 pieces of cereal were noted (latency to find food). The same test was held over four consecutive days, 1 trial per day. Data was collected measuring the number of working memory errors (entering an arm containing food that had previously been entered), and reference memory errors (entering an arm that was not baited) (Foyet et al., 2011; Hritcu et al., 2012) .
Enzyme linked immunosorbent assay
Enzyme linked immunosorbent assay (ELISA) kits were purchased from R & D (R & D Systems, Minneapolis, MN, USA). Frozen rain tissues from both hemispheres, were mixed and homogenized on ice in 0.01 M PBS (pH, 7.4) and centrifuged at 10,000 rpm for 15 min at 4°C. The supernatants were then collected and stored at − 80°C until the measurements of Interleukin 1 beta (IL-1β), Tumor Necrosis Factoralpha (TNF-α), Interleukin 4 (IL-4), Interleukin 10 (IL-10), Brainderived neurotrophic factor (BDNF) and Nerve Growth Factor (NGF) were undertaken. The serum collected before euthanasia was centrifuged at 10,000 rpm for 6 min at 4°C and stored at − 20°C, until the measurement of IL-1β, TNF-α, IL-4 and IL-10 by ELISA was performed as per the manufacturer's instructions. All samples were measured in duplicate and adjusted according to the protein content determined by Lowry et al. (1951) . The results are expressed as picogram per milligram of protein.
Statistical analysis
Statistical analyses were performed using Statistica software 8.0 (StatSoft Inc., Tulsa, USA). Data from ELISA analysis were analyzed by two-way ANOVA followed by the Tukey post hoc test. Mauchly's test of sphericity was used (assumption of violated sphericity) and repeated measurements using the two-way ANOVA test were undertaken to assess radial arm-maze task data following Newman-Keuls post hoc test. The correlation between total errors in the radial arm-maze task and cytokines was performed by Pearson analysis. The data was reported as mean ± SEM, and p values < 0.05 were considered statistically significant.
Results
Repeated measures via Two-way ANOVA were used to analyze our results. Four groups as the between-model factor and treatment as the within-subjects factor showing a statistical difference when observing the latency to find food (F(3.72) = 4.48; p < 0.05), total errors to find food [F(3.72) = 11.97; p < 0.001], reference memory errors [F(3.72) = 16.57; p < 0.0001] and working memory errors [F(3.72) = 10.25; p < 0.001]. The animals that received administrations of Aβ oligomer presented spatial memory impairments when compared to the control group (receiving ACSF) when observing the latency to find food on the 2nd, 3rd, and 4th days of the test (p < 0.01). Minocycline was shown to reverse this effect on the 3rd, (p < 0.05) and 4th (p < 0.01) days (Fig. 1A) . Fig. 1B shows the total errors to find food. In this case, the animals that received administrations of Aβ oligomer made more errors than the control group from the 2nd day of the test (p < 0,01). The animals that received minocycline committed less errors when compared with the animals that received administrations of Aβ oligomer (2nd and 3rd Days: p < 0.01; and 4th: p < 0.0001). When comparing reference memory (Fig. 1C) , the AD-like model animals entered an arm that was not baited more times than the control group animals (p < 0.01). However, when treated with minocycline, their reference memory was restored when compared to the AD-like model on the 2nd, 3rd (p < 0.01), and 4th days of testing (p < 0.001). Fig. 1D shows that minocycline restored working memory on the 2nd, 3rd (p < 0,01) and 4th days of testing (p < 0.001) when compared to the AD-like model group, which presented working memory impairments when compared to the control group on the 2nd, 3rd (p < 0.01) and 4th days of testing (p < 0.001). Fig. 2 shows the levels of IL-1β, which increased in the animals that received Aβ oligomer when compared to the control animals. Minocycline was able to reverse this effect ( Fig. 2A) . The interaction between model factor and treatment in the total cortex [F(1.12) = 17.45; p < 0.01], hippocampus [F(1.12) = 21.89; p < 0.01] (Fig. 2B) , and serum (F(1.13) = 5.40; p < 0.05) is shown in Fig. 2C . In addition, there was a positive correlation between the levels of IL-1β in the hippocampus and total errors to find food (Fig. 2D) , showing that the animals that made more errors while completing the task had increased levels of IL-1β (Pearson r = 0.23; p < 0.05), which is a pro-inflammatory cytokine. This indicates a positive correlation between neuroinflammation and spatial memory impairment.
The levels of TNF-α are shown in Fig. 3 . In the group that received Aβ oligomers increased TNF-α levels in the total cortex and hippocampus. However, there was no increase in the serum. Minocycline was able to reverse this effect in both the total cortex (Fig. 3A) [F(1.12) = 14.69; p < 0.01], and in the hippocampus [F(1.12) = 6.44; p < 0.05] as shown in Fig. 3B . There was no statistical difference in the serum. However, in the total cortex, there was a positive correlation (Pearson r = 0.26; p = 0.01) between the levels of TNF-α and total errors to find food (Fig. 3D) , again correlating pro-inflammatory cytokines and memory impairment. Fig. 4 shows the levels of IL-4. Minocycline reversed the increase in the levels of IL-4 caused by the administration of Aβ within the total cortex [F(1.12) = 5.86; p < 0.05], but there was no effect seen for minocycline in the hippocampus [F(1.12) = 0.35; p = 0.56], although the model has caused increases of this cytokine (p < 0.01). In the serum, minocycline reversed the increases caused by the administration of Aβ [F(1.12) = 9.64; p < 0.01]. In addition, there was a positive correlation (Pearson r = 0.50; p < 0.001) between the levels of IL-4 and total errors to find food (Fig. 3D) , again correlating pro-inflammatory cytokines and memory impairment, and showing a relationship between the levels of IL-4 and spatial memory impairment.
The levels of IL-10 were represented in Fig. 5 . There was no statistical difference in the total cortex amongst any of the groups (Fig. 5A) [F(1.13) = 0.78; p = 0.39]. In the hippocampus (Fig. 5B) , we observed an increase in the levels of IL-10 in the animals that had received administrations of Aβ [F(1.13) = 5.59; p < 0.05], when compared to the control group. Minocycline reversed this effect (p < 0.01). In the serum (Fig. 5C) , administrations of Aβ decreased the levels of IL-10 when compared to the control group [F(1.13) = 4.81; p < 0.05], and minocycline was unable to increase these levels to the same point as those seen in the control group. There was a positive correlation (Pearson r = 0.32; p < 0.01) between the levels of IL-10 observed in the hippocampus and the total number of errors to find food (Fig. 5D ). Fig. 6 shows the levels of BDNF and NGF. Minocycline was shown to reverse the increase in the levels of BDNF caused by the administration of Aβ in the hippocampus [F(1.13) = 11.53; p < 0.01], (Fig. 6A) , but in the total cortex (Fig. 6B ), there were no statistical differences amongst the groups [F(1.13) = 0.50; p = 0.49]. In relation to the levels of NGF, there were no statistical differences in the hippocampus (Fig. 6B) [F(1.13) = 0.51; p = 0.48]. However, in the total cortex (Fig. 6D) , the levels of NGF were found to have increased due to the administration of Aβ, but this was reversed by treatments with minocycline [F(1.13) = 5.39; p < 0.05].
Discussion
In the present study, the administration of Aβ oligomers was able to cause memory damage in the radial arm-maze task. In the early stages of AD, patients present visuospatial disorientation and visuospatial memory impairment (Foxe et al., 2016; Mapstone et al., 2003) . Therefore, our AD-like animal model induced by Aβ oligomers was able to Fig. 1 . The effect of minocycline (50 mg/kg) in the radial arm-maze task performed on BALB/c mice that were subjected to an AD-like model induced by the administration of Aβ (1-42) oligomers. Panel (A) shows the total input error made by animals entering the arms to find the food. Panel (B) shows the latency to find the food in seconds. Panel (C) shows the number of entries into arms containing no food, which were considered the reference for memory errors and (D) shows the number of entries into arms in which the food had been previously consumed, considered to be working memory errors. In all of the parameters that were analyzed, the animals that had received minocycline treatment had a better performance than the animals subjected to an AD-like model, showing the effect that minocycline has in improving the memory impairments caused by the administration of Aβ (1-42) oligomers. Data were analyzed by repeated measures of ANOVA, followed by the Newman-Keuls post hoc test. The data are expressed as mean ± standard error of mean for 9-11 animals per group, *p < 0.05 when compared to ACSF + water group, #p < 0.05 when compared to Aβ1-42 + minocycline group. Fig. 2 . The effect of minocycline (50 mg/kg) on the levels of IL-1β (pg/mL) in relation to BALB/c mice subjected to an AD-like model induced by the administration of Aβ (1-42) oligomers. Panel (A) shows the levels of IL-1β (pg/mL) in the total cortex; (B) shows the levels of IL-1β (pg/mL) in the hippocampus, and panel (C) in the serum. The administration of Aβ (1-42) oligomers caused an increase in the levels of IL-1β, and minocycline was shown to reverse this effect. Panel (D) shows a positive correlation between the levels of IL-1β in the hippocampus and the total errors to find food. Data were analyzed by two-way ANOVA followed by the Tukey post hoc test. The data are expressed as mean ± standard error of the mean of 4-6 animals per group, *p < 0.05 compared to ACSF + water group, #p < 0.05 compared to Aβ1-42 + water group. Fig. 3 . The effect of minocycline (50 mg/kg) on the levels of TNF-α (pg/mL) in relation to BALB/c mice subjected to an AD-like model induced by the administration of Aβ (1-42) oligomers. Panel (A) shows the levels of TNF-α (pg/mL) in the total cortex; (B) shows the levels of TNF-α (pg/mL) in the hippocampus, and panel (C) shows the levels of TNF-α (pg/mL) in the serum. The administration of Aβ (1-42) oligomers caused an increase in the levels of TNF-α, and minocycline was able to reverse this effect in the brain structures, but not in the serum; and (D) which shows a positive correlation between the levels of TNF-α in the total cortex and the total errors to find food. Data were analyzed by two-way ANOVA followed by the Tukey post hoc test. The data are expressed as mean ± standard error of the mean of 4-6 animals per group, *p < 0.05 compared to ACSF + water group, #p < 0.05 compared to Aβ1-42 + water group. Minocycline reversed the increase in the levels of IL-4 caused by the administration of Aβ (1-42) oligomers in the total cortex and serum, but not in the hippocampus; and (D) shows a positive correlation between the levels of IL-4 in the total cortex and the total errors to find food. Data were analyzed by two-way ANOVA followed by the Tukey post hoc test. The data are expressed as mean ± standard error of the mean of 4-6 animals per group, *p < 0.05 compared to ACSF + water group, #p < 0.05 compared to Aβ1-42 + water group. (1-42) oligomers. Panel (A) shows the levels of IL-10 (pg/mL) in the total cortex; (B) shows the levels of IL-10 levels (pg/mL) in the hippocampus, and panel (C) shows the levels of IL-10 (pg/mL) in the serum. Minocycline reversed the increase in the levels of IL-10 caused by the administration of Aβ (1-42) oligomers only in the hippocampus; and (D) shows a positive correlation between the levels of IL-10 in the hippocampus and the total errors to find food. Data were analyzed by two-way ANOVA followed by the Tukey post hoc test. The data are expressed as mean ± standard error of the mean of 4-6 animals per group, *p < 0.05 compared to ACSF + water group, #p < 0.05 compared to Aβ1-42 + water group. (1-42) oligomers. Panel (A) shows the levels of BDNF in the hippocampus; (B) shows the levels of BDNF in the total cortex. Minocycline was able to reduce the increases seen in the levels of BDNF caused by the administration of Aβ (1-42) oligomers in the hippocampus. Panel (C) shows the NGF levels in the hippocampus and (D) in the total cortex. The administration of Aβ (1-42) oligomers increased the levels of NGF only in the total cortex, and minocycline was able to decrease these levels. Data were analyzed by two-way ANOVA followed by Tukey post hoc test. The data are expressed as mean ± standard error of the mean of 4-6 animals per group, *p < 0.05 compared to ACSF + water group, #p < 0.05 compared to Aβ1-42 + water group.
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Progress in Neuropsychopharmacology & Biological Psychiatry 77 (2017) 23-31 cause spatial memory impairment similar to that observed in AD patients. There have been numerous clinical pathological studies attempting to correlate amyloid plaques with the cognitive deficits seen in AD (Markesbery et al., 2006; Nelson et al., 2007; Robinson et al., 2011; Sabbagh et al., 2010; Small et al., 2006; Tiraboschi et al., 2004) , and also to show that soluble amyloid, present as small oligomers, is capable of causing toxic insult to the brain (Guillozet et al., 2003; Walsh et al., 2002; Wang et al., 2016) . However, these studies have many limitations, see more at Nelson et al. (2012) . Furthermore, other studies have failed to find this correlation, and do not support the "Amyloid Cascade Hypothesis", especially after the failure of immunization against Aβ 1-42 in patients (Gilman et al., 2005; Hardy, 2006; Holmes et al. 2008; Karran and De Strooper, 2016; Zotova et al., 2013) . So, although not unheard of (Liu et al., 2015) , our findings should be highlighted. In addition, the present study shows that minocycline was able to reverse spatial memory impairments caused by the administration of Aβ oligomers. Other studies have also evaluated the effects of minocycline on spatial memory using the rodent model of AD. In some of these studies, minocycline was shown to reverse the damage to spatial memory (Biscaro et al., 2012; Bruno et al., 2009; Choi et al., 2007; Parachikova et al., 2010) . However, another study found it did not ameliorate cognitive impairment (Seabrook et al., 2006) . It must be noted that all of these studies used the water maze test to evaluate spatial memory, whereas the present study utilized the radial arm-maze task. Thus, our study assessed working memory and reference memory, and also showed the effects of minocycline on these kind of memories, since working memory and reference memory impairments are common features found in patients suffering with AD (Aggarwal et al., 2005; Mapstone et al., 2003) .
Neuroinflammation is present in the asymptomatic and advanced stages of AD. Aβ oligomers activate microglia, which causes inflammation in the brain and promotes the production of cytokines and other inflammatory mediators that might contribute to dysfunction, injury, and ultimately neuronal loss (Ferretti et al., 2012; Heneka et al., 2014) . Innate immune activation and neuroinflammation are present in various neurodegenerative diseases and indeed may be involved in promoting these conditions (Heneka et al., 2014) . In addition, blood concentrations of several inflammatory mediators, including TNF-α, IL-6, and IL-1β are increased in patients suffering with AD (Swardfager et al., 2010) .
In the present study, minocycline was shown to reverse the increases in the levels of IL-1β and TNF-α in the brain structures evaluated in this study, and reduced the level of IL-1β in the serum. Hunter et al. (2004) , also observed that minocycline reduced the levels of IL-1β and TNF-α gene expression in basal forebrain lesions induced by p75-saporin immunotoxin. In addition to this, minocycline reduced IL-1β and TNF-α in vitro (Seabrook et al., 2006) , and in 3xTg-AD mice, minocycline reduced the levels of TNF-α, and other pro-inflammatory markers (Parachikova et al., 2010) . In another study, minocycline reduced IL-1β content from pre-plaques in McGill-Thy1-APP mice (Ferretti et al., 2012) . However, Garwood et al. (Garwood et al., 2010) found that minocycline treatments resulted in significantly increased levels of IL-1β in the cortex of Tau transgenic mice. Thus, it is the first time that the effects of minocycline on these pro-inflammatory cytokines has been observed in an AD-like dementia model induced via the administration of Aβ oligomers.
In addition, the results relating to the total cortex show there was a positive correlation between the levels of TNF-α and total errors to find food. The cortex in rodents supports a variety of processes associated with executive function including working memory, temporal processing, planning, rule learning, and decision-making (Kesner and Churchwell, 2011) . Higher concentrations of TNF-α were associated with smaller hippocampal volumes and cognitive function in the elderly (Sudheimer et al., 2014) . Our study shown positive correlation only in the cortex, maybe because the increase of TNF-α levels in the cortex was 3-fold bigger in the animals received Aβ oligomers compared to the control animals, and in the hippocampus only 2-fold bigger. Other study also observed differences between cytokines production in the cortex and hippocampus. In 3xTg-AD mice there was an increase in the TNF-α and MCP-1 expression within the entorhinal cortex, but no change was detected in the hippocampus, indicating that a regional difference exists between the entorhinal cortex and hippocampus in the intensity of the inflammatory process (Janelsins et al., 2005) .
In the hippocampus, there was a positive correlation between the levels of IL-1β and total errors to find food. These results show a directly correlation between the memory impairments and the increased levels of pro-inflammatory cytokines. Some studies have already observed the ability of interleukin-1β to inhibit long-term potentiation in the hippocampus (Murray and Lynch, 1998; Nolan et al., 2005; O'Donnell et al., 2000) . Thus, IL-1β levels in the hippocampus seem directly linked with cognitive impairment, agreeing with our finding that there was a positive correlation between the levels of IL-1β and cognitive damage in this structure. In the hippocampus of 10 months old senescence accelerated mouse (SAM) P8, with the expression of IL-1β mRNA was significantly elevated only on the hippocampus (Tha et al., 2000) .
Our results have also shown that minocycline reversed the increases in the levels of IL-4 caused by the administration of Aβ within the total cortex and in the serum. Furthermore, there was a positive correlation between the level of IL-4 and spatial error damage in the cortex, but not in the hippocampus. The cortex in rodents is important for executive function and working memory, as mentioned above. There is not still a reason for no correlation in the hippocampus, but additional studies are needed to clarify this point. Additionally, minocycline reversed the increase in the levels of IL-10 within the hippocampus of animals that received administrations of Aβ. There was also a positive correlation between the levels of IL-10 and memory impairment. IL-10 is a potent suppressor of TNF-α, IL-1β, and IL-6, and limits inflammation in the brain (Strle et al., 2001) . In vitro studies, IL-10 suppressed Aβ peptideinduced inflammatory cytokines in rats (Ledeboer et al., 2000; Szczepanik et al., 2001) . Although IL-4 and IL-10 cytokines are known as anti-inflammatory mediators, a recent meta-analyses study has reported an association between IL-10 gene polymorphisms and the risk of developing AD (Mun et al., 2016) . Studies have shown that the IL-10 signaling pathway is abnormally elevated in the serum (Gezen-Ak et al., 2013) and in the brain samples taken from AD patients (GuillotSestier et al., 2015) . Furthermore, it was shown that IL-10 can impair glial Aβ phagocytosis and had a pro-amyloidogenic effect in APP mice (Chakrabarty et al., 2015) . It was also demonstrated that an overexpression of IL-4 within the hippocampus of APP transgenic mice leads to exacerbation of amyloid deposition in vivo (Chakrabarty et al., 2012) . Thus, this data further highlights the complex role that innate immune activation plays in neurodegenerative diseases.
Studies concerning the role of the neurotrophins in AD tend to focus mainly on NGF and BDNF, and their effect in maintaining synaptic plasticity and contact with the neurons of the hippocampus and cortex (Allen et al., 2011) . In the present study, Aβ administration caused an increase in the levels of BDNF and NGF within the hippocampus and total cortex. Some studies have observed a decrease in the levels of BDNF in the hippocampus of AD patients (Gezen-Ak et al., 2013; Holsinger et al., 2000; Peng et al., 2005) , but other studies have shown that it was increased (Angelucci et al., 2010; Faria et al., 2014) . In addition, it was observed that BDNF is upregulated near Aβ plaques where an immune response is evoked by activated glial cells (Burbach et al., 2004) , with TNF-α and IL-6 enhancing the production of BDNF via cultured monocytes (Schulte-Herbruggen et al., 2005) . Therefore, decreased levels of BDNF can be observed in the later stages of the disease, and an increase is seen in the earlier stages, which may be a regulatory mechanism of memory loss (Budni et al., 2015b) . This was observed in our study, where Aβ oligomers caused memory impairment and increases in the levels of BDNF, but minocycline was able to reverse both of these alterations.
The post-mortem brain from AD patients showed a deficit in the cascade responsible for the conversion of pro form of NGF (pro-NGF) into mature NGF (Bruno et al., 2009 ). The levels of NGF and pro-NGF were found to be significantly elevated in the frontal cortex (Hellweg et al., 1998; Hock et al., 2000; Pedraza et al., 2005; Peng et al., 2004; Podlesniy et al., 2006) , parietal cortex (Fahnestock et al., 1996; Podlesniy et al., 2006) and cerebrospinal fluid (Blasko et al., 2006) of AD patients. In our study, treatment with minocycline reversed the increase in the levels of NGF. However, our results do not show both forms of NGF, with our data more likely showing the combination of both of these forms, with minocycline being able to reduce these levels. Bruno et al. (2009) also observed that minocycline provides significant protection from the up regulation of pro-NGF induced by Aβ in transgenic mice. In addition to this, in microglial retinal cells, minocycline reduced the precursor form of NGF, thus protecting the cells against apoptosis (Yang and Duan, 2013) .
In conclusion, our study showed an important role for minocycline in helping to prevent cognitive impairment by inducing increases in the levels of neurotrophins and cytokines in the brain structures and serum. In addition, we showed that cognitive spatial impairment can be related to pro-and anti-inflammatory cytokines. Therefore, since neuroinflammation is a consistent mechanism involved in AD, our results reinforce the anti-inflammatory effects of minocycline as well as its effects on cognition and neurotrophins. We have great hope that future clinical trials confirmed the benefits of minocycline. However, are needed more studies to elucidate other potential mechanisms of action for minocycline.
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